Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
-
121
-
122
-
123
-
124
-
125
-
126
Drugs susceptibility profile (EC<sub>50</sub> values and Fold-change) to the antileishmanials in all polyene resistant lines of <i>Leishmania</i> spp.
Published 2022“…Values higher and lower than 1, indicate a decrease and increase in susceptibility, respectively.…”
-
127
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
128
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
129
-
130
-
131
Description of the cohort (N = 118 patients).
Published 2023“…An HLA-G plasma level ≤ 50 ng/ml on day 8 after LT was significantly associated with a higher rejection risk. …”
-
132
-
133
The <i>rcan-1</i> rearrangement allele decreases expression of <i>rcan-1</i>.
Published 2020“…The gene with the largest and most significant expression decrease was <i>rcan-1</i>. Red: p<0.01, log<sub>2</sub>(Fold Change) > 1. …”
-
134
-
135
-
136
-
137
-
138
-
139
-
140